The most commonly used medications to treat OAB have anticholinergic properties. Anticholinergics are competitive inhibitors of acetylcholine at muscarinic receptors (mainly the M3 receptor ...

Sumitomo Pharma's Gemtesa (vibegron) has been approved by the U.S. Food and Drug Administration for men with overactive ...

The standard treatments for overactive bladder include lifestyle changes, bladder training, pelvic floor muscle training and anticholinergic (anti-muscarinic) drugs. Additional treatments for some ...

The FDA has approved Gemtesa® for men with overactive bladder symptoms receiving pharmacological therapy for BPH.

Because the exact cause of OAB is unknown, the condition can be difficult to treat and often requires a multifactorial approach involving lifestyle, medications, and specialized procedures.

An overactive bladder may be temporary or become a chronic condition. How long the symptoms last may depend on factors like the underlying cause and treatment adherence. Some conditions may cause ...

The platform is designed to highlight the impact of OAB symptoms and educate on disease management, including information on treatment options, such as GEMTESA® (vibegron). In this exclusive with ...

Treatment with vibegron reduced the average number of micturition episodes per day and the average number of daily urgency episodes compared with placebo. The Food and Drug Administration (FDA ...